secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0001683168-25-004421
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharmaceuticals appoints Lisa Carson as CFO/PAO; Infarinato shifts to VP Strategic Development
--------------------------------------------------------------------------------

- Lisa Carson named VP Finance and Administration and designated principal financial and accounting officer, effective June 6, 2025.
- Robert Infarinato ceased as PFO/PAO, appointed VP Strategic Development effective June 9 to focus on INTASYL portfolio business development.
- Carson's compensation: $290k base salary, up to 30% annual bonus, $25k sign-on stipend; at-will employment.
- Company announces strategic initiative to raise awareness of INTASYL siRNA portfolio (~30 compounds); positive interim Phase 1b results for PH-762 in skin cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825004421/0001683168-25-004421-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825004421/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-004421

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer